David E. Gerber
#161,629
Most Influential Person Now
Researcher
David E. Gerber's AcademicInfluence.com Rankings
David E. Gerbercomputer-science Degrees
Computer Science
#9348
World Rank
#9821
Historical Rank
Computational Linguistics
#2241
World Rank
#2264
Historical Rank
Machine Learning
#4066
World Rank
#4115
Historical Rank
Artificial Intelligence
#4406
World Rank
#4467
Historical Rank
Download Badge
Computer Science
David E. Gerber's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science University of California, Berkeley
- Bachelors Computer Science University of California, Berkeley
Similar Degrees You Can Earn
Why Is David E. Gerber Influential?
(Suggest an Edit or Addition)David E. Gerber's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. (2015) (7370)
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. (2017) (765)
- Consolidative Radiotherapy for Limited Metastatic Non–Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial (2018) (610)
- Paraneoplastic syndromes: an approach to diagnosis and treatment. (2010) (510)
- Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. (2016) (414)
- Targeted therapies: a new generation of cancer treatments. (2008) (412)
- Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. (2011) (387)
- Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. (2016) (380)
- Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. (2014) (236)
- ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. (2010) (217)
- Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer (2021) (180)
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events (2021) (168)
- Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? (2016) (141)
- Management of venous thromboembolism in patients with primary and metastatic brain tumors. (2006) (139)
- Nivolumab Plus Erlotinib in Patients With EGFR‐Mutant Advanced NSCLC (2018) (131)
- Maintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea. (2013) (129)
- Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. (2015) (123)
- Stigma among patients with lung cancer: a patient‐reported measurement model (2014) (118)
- The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1514 patients undergoing hematopoietic stem cell transplantation: implications for VTE prevention. (2008) (111)
- Development and Validation of a Nomogram Prognostic Model for SCLC Patients (2018) (104)
- Results from ARQ 197-209: A global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). (2010) (103)
- Autoimmunity, Checkpoint Inhibitor Therapy and Immune-related Adverse Events: A Review. (2020) (102)
- Prevalence of Autoimmune Disease Among Patients With Lung Cancer: Implications for Immunotherapy Treatment Options. (2016) (101)
- Prevalence of Prior Cancer Among Persons Newly Diagnosed With Cancer: An Initial Report From the Surveillance, Epidemiology, and End Results Program (2017) (101)
- The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. (2007) (100)
- Immune dysregulation in cancer patients developing immune-related adverse events (2018) (99)
- Targeted Therapies for Lung Cancer: Clinical Experience and Novel Agents (2011) (99)
- Impact of prior cancer on eligibility for lung cancer clinical trials. (2014) (92)
- ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non–Small Cell Lung Cancer (2015) (90)
- A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma. (2012) (90)
- BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer (2013) (90)
- Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Combination With Platinum-Based Doublet Chemotherapy (PT-DC) in Advanced Non-Small Cell Lung Cancer (NSCLC) (2014) (89)
- Lung Cancer Diagnostic and Treatment Intervals in the United States: A Health Care Disparity? (2009) (87)
- Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. (2016) (86)
- Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual. (2015) (86)
- Management and future directions in non-small cell lung cancer with known activating mutations. (2014) (83)
- CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. (2016) (78)
- Predictors and intensity of online access to electronic medical records among patients with cancer. (2014) (73)
- Acquired Resistance to First‐Line Afatinib and the Challenges of Prearranged Progression Biopsies (2016) (70)
- Phase I Safety and Pharmacokinetic Study of Bavituximab, a Chimeric Phosphatidylserine-Targeting Monoclonal Antibody, in Patients with Advanced Solid Tumors (2011) (65)
- Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. (2019) (61)
- TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer (2018) (60)
- Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy. (2018) (57)
- Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). (2014) (56)
- Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial. (2015) (56)
- Targeting the PI3K pathway for cancer therapy. (2012) (55)
- Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis. (2020) (55)
- Looking Beyond Surveillance, Epidemiology, and End Results: Patterns of Chemotherapy Administration for Advanced Non-small Cell Lung Cancer in a Contemporary, Diverse Population (2010) (49)
- Histologic Transformation from Adenocarcinoma to Squamous Cell Carcinoma as a Mechanism of Resistance to EGFR Inhibition. (2015) (49)
- Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone (2015) (48)
- Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment. (2011) (47)
- A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). (2013) (47)
- Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis (2018) (46)
- A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). (2015) (45)
- EGFR inhibition in the treatment of non‐small cell lung cancer (2008) (44)
- Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer (2017) (44)
- Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). (2017) (43)
- Prior cancer does not adversely affect survival in locally advanced lung cancer: A national SEER-medicare analysis. (2016) (43)
- DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden (2020) (43)
- Predictors and Impact of Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer in the United States: Real-World Considerations for Maintenance Therapy (2011) (42)
- Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical center. (2012) (42)
- Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors (2019) (41)
- EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer (2020) (41)
- Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used? (2019) (41)
- Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets). (2016) (40)
- First-Line Monotherapy With Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Advanced Non-Small Cell Lung Cancer (NSCLC): Safety, Efficacy, and Correlation of Outcomes With PD-L1 Status (2014) (38)
- First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. (2015) (38)
- Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and Complexity (2017) (38)
- Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer. (2014) (37)
- Phase 1 study of romidepsin plus erlotinib in advanced non-small cell lung cancer. (2015) (36)
- P2.36: Nivolumab (nivo) in Patients (pts) With Advanced (adv) NSCLC and Central Nervous System (CNS) Metastases (mets): Track: Immunotherapy. (2016) (36)
- Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer. (2010) (33)
- Stromal Platelet-Derived Growth Factor Receptor α (PDGFRα) Provides a Therapeutic Target Independent of Tumor Cell PDGFRα Expression in Lung Cancer Xenografts (2012) (32)
- OA14.04 Five-Year Outcomes From the Randomized, Phase 3 Trials CheckMate 017/057: Nivolumab vs Docetaxel in Previously Treated NSCLC (2019) (31)
- Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy (2018) (31)
- Axl Receptor Axis: A New Therapeutic Target in Lung Cancer (2016) (31)
- Cetuximab in combination therapy: from bench to clinic (2010) (30)
- Should criteria for inclusion in cancer clinical trials be expanded? (2015) (30)
- Access to Investigational Drugs: FDA Expanded Access Programs or “Right‐to‐Try” Legislation? (2015) (30)
- Baseline tumour measurements predict survival in advanced non-small cell lung cancer (2013) (27)
- Venous thromboembolism occurs infrequently in meningioma patients receiving combined modality prophylaxis (2007) (27)
- Phase 2 Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin with Concurrent Radiation Therapy Followed by Pemetrexed Consolidation in Patients with Favorable-Prognosis Inoperable Stage IIIA/B Non–Small-Cell Lung Cancer (2013) (26)
- ALK alterations and inhibition in lung cancer. (2017) (26)
- A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC). (2014) (25)
- Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation. (2015) (25)
- Treatment and Outcomes of Primary Pericardial Mesothelioma: A Contemporary Review of 103 Published Cases (2019) (25)
- Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer. (2013) (25)
- Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer (2018) (24)
- Patient comprehension and attitudes toward maintenance chemotherapy for lung cancer. (2012) (24)
- The impact of consenter characteristics and experience on patient interest in clinical research. (2009) (22)
- Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial. (2021) (21)
- Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. (2015) (21)
- Outcomes of neoadjuvant and adjuvant chemotherapy in stage 2 and 3 non-small cell lung cancer: an analysis of the National Cancer Database (2018) (20)
- Increase in Cancer Center Staff Effort Related to Electronic Patient Portal Use. (2016) (20)
- Resolving Rivalries and Realigning Goals: Challenges of Clinical and Research Multiteam Systems. (2016) (20)
- Using a novel NQO1 bioactivatable drug, beta‐lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer (2017) (20)
- NQO1-dependent, Tumor-selective Radiosensitization of Non–small Cell Lung Cancers (2019) (19)
- Nivolumab (N) plus ipilimumab (I) as first-line (1L) treatment for advanced (adv) NSCLC: 2-yr OS and long-term outcomes from CheckMate 012. (2017) (19)
- Phase Ia Study of Anti-NaPi2b Antibody–Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non–Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer (2019) (19)
- Locally Advanced Lung Cancer: An Optimal Setting for Vaccines and Other Immunotherapies (2013) (19)
- A Phase Ib Dose‐Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS (2017) (19)
- Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma. (2019) (18)
- Recent advances in radiation therapy. (2008) (18)
- Tumor-specific targeting by Bavituximab, a phosphatidylserine-targeting monoclonal antibody with vascular targeting and immune modulating properties, in lung cancer xenografts. (2015) (18)
- Hyperprogressive disease: a distinct effect of immunotherapy? (2019) (18)
- Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non-Small-Cell Lung Cancer. (2016) (17)
- Conceptual Model for Accrual to Cancer Clinical Trials. (2019) (17)
- Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling (2019) (17)
- Late‐Onset Immunotherapy Toxicity and Delayed Autoantibody Changes: Checkpoint Inhibitor–Induced Raynaud's‐Like Phenomenon (2020) (17)
- Consent timing and experience: modifiable factors that may influence interest in clinical research. (2012) (16)
- Type and case volume of health care facility influences survival and surgery selection in cases with early‐stage non–small cell lung cancer (2019) (16)
- A phase I study of the safety and pharmacokinetics of DNIB0600A, an anti-NaPi2b antibody-drug-conjugate (ADC), in patients (pts) with non− small cell lung cancer (NSCLC) and platinum-resistant ovarian cancer (OC). (2013) (16)
- ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC. (2020) (16)
- Temporal Trends and Predictors for Cancer Clinical Trial Availability for Medically Underserved Populations. (2015) (16)
- Five-year outcomes from the randomized, phase 3 trials CheckMate 017/057: nivolumab vs docetaxel in previously treated NSCLC (2020) (16)
- Emerging monoclonal antibody therapies for malignant gliomas (2007) (16)
- Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer. (2017) (16)
- Unique Patterns of Distant Metastases in HPV-Positive Head and Neck Cancer (2019) (15)
- Histologic transformation of EGFR mutant lung adenocarcinoma without exposure to EGFR inhibition. (2017) (15)
- Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma (2007) (15)
- Patient navigation for lung cancer screening in an urban safety-net system: Protocol for a pragmatic randomized clinical trial. (2017) (14)
- How does autoimmune disease impact treatment and outcomes among patients with lung cancer? A national SEER-Medicare analysis. (2018) (14)
- Main bronchus location is a predictor for metastasis and prognosis in lung adenocarcinoma: A large cohort analysis. (2018) (14)
- Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. (2018) (14)
- ORAL01.03: CheckMate 012: Safety and Efficacy of First‐Line Nivolumab and Ipilimumab in Advanced NSCLC: Topic: Medical Oncology (2016) (14)
- A reevaluation of CD22 expression in human lung cancer. (2014) (14)
- Consolidative Radiotherapy for Limited Metastatic Non–Small Cell Lung Cancer: A Randomized Phase 2 Trial (2017) (14)
- Phase Ib KEYNOTE-200: A study of an intravenously delivered oncolytic virus, coxsackievirus A21 in combination with pembrolizumab in advanced NSCLC and bladder cancer patients. (2018) (13)
- Going into BATTLE: umbrella and basket clinical trials to accelerate the study of biomarker-based therapies. (2016) (13)
- Brief report: Preliminary clinical and molecular analysis results from a single arm phase 2 trial of brigatinib in patients with disease progression after next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in advanced ALK + non-small cell lung cancer. (2020) (13)
- Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways (2015) (13)
- Maintenance therapy for advanced lung cancer: who, what, and when? (2013) (13)
- OA 17.03 First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update (2017) (13)
- Chemotherapy for Advanced Non-small Cell Lung Cancer. (2016) (12)
- Association between immune-related adverse event timing and treatment outcomes (2022) (12)
- Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC). (2019) (12)
- 1054PDNIVOLUMAB (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH PLATINUM-BASED DOUBLET CHEMOTHERAPY (PT-DC) OR ERLOTINIB (ERL) IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (11)
- Beyond adenocarcinoma: current treatments and future directions for squamous, small cell, and rare lung cancer histologies. (2015) (11)
- 253 Phase 1 correlative study of ARQ761, a β-lapachone analogue that promotes NQ01-mediated programmed cancer cell necrosis (2014) (11)
- 3096 First-line monotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy, and biomarker analyses (2015) (11)
- Randomized, blinded, placebo-controlled phase II trial of docetaxel and bavituximab as second-line therapy in locally advanced or metastatic non-squamous non-small cell lung cancer. (2013) (11)
- Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI. (2016) (11)
- Experience, Perceptions, and Recommendations Concerning COVID-19-Related Clinical Research Adjustments. (2020) (11)
- How Have We Diagnosed Early-Stage Lung Cancer without Radiographic Screening? A Contemporary Single-Center Experience (2012) (11)
- Effect of Prior Cancer on Outcomes in Advanced Lung Cancer: Implications for Clinical Trial Eligibility and Accrual (2014) (11)
- Phase II study of olaratumab with paclitaxel/carboplatin (P/C) or P/C alone in previously untreated advanced NSCLC. (2017) (11)
- Characteristics of Patients Using Patient Portals in Oncology (2018) (11)
- A randomized trial of mail and email recruitment strategies for a physician survey on clinical trial accrual (2020) (10)
- Timing, Sites, and Correlates of Lung Cancer Recurrence. (2019) (10)
- Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors (2021) (10)
- Immunotherapy for non-small cell lung cancer: from clinical trials to real-world practice. (2019) (10)
- EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): The newest study in the ALCHEMIST platform. (2017) (10)
- Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non–Small Cell Lung Cancer (2020) (9)
- Application of Information Technology to Clinical Trial Evaluation and Enrollment: A Review. (2021) (9)
- Oncology Nursing Perceptions of Patient Electronic Portal Use: A Qualitative Analysis (2017) (9)
- DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors (2019) (9)
- Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group (2021) (9)
- Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. (2017) (9)
- Randomized phase III trial of concurrent chemoradiation followed by nivolumab or placebo for locally advanced non-small cell lung cancer (NSCLC) (RTOG 3505). (2017) (9)
- Patient and provider perspectives on delivery of oral cancer therapies. (2019) (8)
- Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung Cancer (2019) (8)
- Cancer Center Clinic and Research Team Perceptions of Identity and Interactions. (2017) (8)
- OA03.01 First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012 (2017) (8)
- Statin Intolerance, anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A "Two-Hit" Autoimmune Toxicity or Clinical Predisposition? (2020) (8)
- Should family physicians routinely screen for lung cancer in high-risk populations? Yes: CT-based screening is complex but worthwhile. (2014) (8)
- A phase 2 study of defactinib (VS-6063), a cancer stem cell inhibitor that acts through inhibition of focal adhesion kinase (FAK), in patients with KRAS-mutant non-small cell lung cancer. (2014) (8)
- Preclinical Development Stromal Platelet-Derived Growth Factor Receptor a ( PDGFR a ) Provides a Therapeutic Target Independent of Tumor Cell PDGFR a Expression in Lung Cancer Xenografts (2012) (7)
- Survival of women diagnosed with breast cancer and who have survived a previous cancer (2021) (7)
- Statistical justification of expansion cohorts in phase 1 cancer trials (2018) (7)
- Estimating lead‐time bias in lung cancer diagnosis of patients with previous cancers (2018) (7)
- Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials (2017) (7)
- ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer. (2015) (7)
- Mobile Device Applications for Electronic Patient Portals in Oncology. (2019) (7)
- A novel polymer gel for the delivery of local therapies to intracranial tumors: In vivo safety evaluation. (2011) (7)
- Understanding the Relationship Between Care Volume and Clinical Outcomes in Multiple Myeloma. (2017) (6)
- Closing the gap: Contribution of surgical best practices to outcome differences between high‐ and low‐volume centers for lung cancer resection (2020) (6)
- A crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. (2017) (6)
- Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors (2022) (6)
- Increasing Numbers and Reported Adverse Events in Patients with Lung Cancer Undergoing Inpatient Lung Biopsies: A Population-Based Analysis (2019) (6)
- Immunotherapy Use in Patients With Lung Cancer and Comorbidities. (2020) (6)
- Taking Tele Behind the Scenes: Remote Clinical Trial Monitoring Comes of Age During the COVID-19 Pandemic. (2021) (6)
- Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508). (2020) (6)
- Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology (2020) (6)
- CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer. (2021) (6)
- Implementation and Uptake of Rural Lung Cancer Screening. (2022) (6)
- Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer. (2020) (5)
- Oncologic emergencies and urgencies: A comprehensive review (2022) (5)
- Rates of appropriate laxative prophylaxis for opioid-induced constipation in veterans with lung cancer: a retrospective cohort study (2020) (5)
- Clinical and biological determinants of circulating tumor DNA detection and prognostication using a next-generation sequencing panel assay (2021) (5)
- P1.01-02 Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012 (2018) (5)
- EGFR ligand shifts the role of EGFR from oncogene to tumour suppressor in EGFR-amplified glioblastoma by suppressing invasion through BIN3 upregulation (2022) (5)
- Association of hypertension (HTN) and clinical outcome in a phase II trial of cisplatin (C), pemetrexed (P), and bevacizumab (B) in patients (pts) with untreated malignant mesothelioma. (2010) (5)
- Humoral and cellular correlates of a novel immune-related adverse event and its treatment (2021) (5)
- Oligometastatic Non-Small-Cell Lung Cancer: How Should We Define and Manage It? (2018) (5)
- Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit? (2019) (5)
- Acquired Resistance to Afatinib in EGFR-Mutant Lung Cancer (2014) (5)
- Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer (2022) (5)
- 1255TiP CheckMate 73L: A phase III study comparing nivolumab (NIVO) plus concurrent chemoradiotherapy (CCRT) followed by NIVO ± ipilimumab (IPI) versus CCRT followed by durvalumab (DURV) for previously untreated, locally advanced (LA) stage III non-small cell lung cancer (NSCLC) (2020) (4)
- Tracking the Nonenrolled: Lung Cancer Screening Patterns Among Individuals not Accrued to a Clinical Trial. (2020) (4)
- Pharmaceutical Perspectives of Cancer Therapeutics: Current Therapeutic Uses of Monoclonal Antibodies (2009) (4)
- Prevalence and Significance of Potential Pharmacokinetic Drug–Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials (2021) (4)
- Pseudoprogression in advanced non-small cell lung cancer treated with combination chemoimmunotherapy: a case report (2022) (4)
- Upper lip metastasis of sarcomatoid carcinoma of the lung – an unusual site of disease: a case report (2017) (4)
- A phase 1 study of veliparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (SCLC) patients: An Eastern Cooperative Oncology Group study (E2511). (2014) (4)
- Association between Antibiotic Exposure and Systemic Immune Parameters in Cancer Patients Receiving Checkpoint Inhibitor Therapy (2022) (4)
- A phase I/II and pharmacokinetic study of BGB324, a selective AXL inhibitor as monotherapy and in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) (2016) (4)
- Impact of NCI-mandated scientific review on protocol development and content. (2015) (4)
- Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update. (2021) (4)
- Phase 1 study of ARQ 761, a β-lapachone analogue that promotes NQO1-mediated programmed cancer cell necrosis (2017) (3)
- QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care. (2019) (3)
- Institutional Scientific Review of Cancer Clinical Research Protocols: A Unique Requirement That Affects Activation Timelines. (2017) (3)
- Increased reporting but decreased mortality associated with adverse events in patients undergoing lung cancer surgery: Competing forces in an era of heightened focus on care quality? (2020) (3)
- Comprehensive genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC). (2016) (3)
- Survival of patients newly diagnosed with colorectal cancer and with a history of previous cancer (2021) (3)
- Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) (2014) (3)
- A phase II trial of second-line erlotinib in combination with stereotactic body radiation therapy (SBRT) for patients with metastatic non-small cell lung cancer (NSCLC). (2013) (3)
- Potential Impact of Revised NCI Eligibility Criteria Guidance: Prior Malignancy Exclusion in Breast Cancer Clinical Trials. (2022) (2)
- Abstract 5337: Phase 1 study of bavituximab in advanced solid tumor malignancies: Final results (2010) (2)
- A randomized phase 2 study of a human antiplatelet-derived growth factor α (PDGFRα) monoclonal antibody (olaratumab, IMC-3G3) with paclitaxel/carboplatin or paclitaxel/carboplatin alone in previously untreated patients with advanced non-small cell lung cancer (NSCLC). (2014) (2)
- Patterns of distant metastases in HPV-positive head and neck squamous cell carcinoma. (2014) (2)
- Consolidation With Pembrolizumab and Nab-Paclitaxel After Induction Platinum-Based Chemotherapy for Advanced Non-Small Cell Lung Cancer (2021) (2)
- Safety, Pharmacokinetics, and Activity of the Anti-NaPi2b Antibody-Drug Conjugate DNIB0600A: A Phase I Study in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer (2013) (2)
- Venous Thromboembolism among 1,570 Patients Undergoing Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, Treatment and Outcomes. (2007) (2)
- Phase II trial of ribociclib and everolimus in p16 low anaplastic thyroid cancer (ATC). (2017) (2)
- Systemic and Intracranial Efficacy of Osimertinib in EGFR L747P-Mutant NSCLC: Case Report (2022) (2)
- Survival of cancer survivors with a new pancreatic cancer diagnosis (2022) (2)
- MA 02.09 A Ph I/II Study of BGB324, a Selective AXL Inhibitor as Monotherapy and in Combination with Erlotinib in Advanced NSCLC (2017) (2)
- Definition and Coordination of Roles and Responsibilities Among Cancer Center Clinic and Research Personnel. (2020) (2)
- Some things get better with age (2015) (2)
- Comprehensive targeting of resistance to inhibition of RTK signaling pathways by using glucocorticoids (2021) (2)
- A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) Combined with Erlotinib for Patients with Recurrent Non-small Cell Lung Cancer (NSCLC) (2010) (2)
- Longitudinal Experience With and Impressions of COVID-19-Related Clinical Research Changes. (2021) (2)
- Choroid plexus papilloma—A case highlighting the challenges of extrapolating pediatric chemotherapy regimens to adult populations (2016) (2)
- Next-Generation Sequencing for the Identification of Targetable Molecular Alterations in Cancer. (2016) (2)
- Clinician Variation in Ordering and Completion of Low-Dose Computed Tomography for Lung Cancer Screening in a Safety-Net Medical System. (2020) (2)
- A phase 1/2 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated non-squamous NSCLC. (2018) (2)
- Phase I and pharmacodynamic study of the histone deacetylase (HDAC) inhibitor romidepsin plus erlotinib in previously treated advanced non-small cell lung cancer (NSCLC). (2013) (1)
- Immune checkpoint inhibition-induced myocarditis in cancer patients: Proposal of a detection and management strategy. (2020) (1)
- Patterns of Failure in Metastatic Non-Small Cell Lung Cancer Patients After Initiation of Pembrolizumab. (2021) (1)
- Reimbursement Matters: Overcoming Barriers to Clinical Trial Accrual. (2021) (1)
- PPHM 1501- An open-label, randomized, phase II trial of durvalumab (MEDI4736) with or without bavituximab in patients with previously treated metastatic non-small cell lung cancer (NSCLC): Safety report on first 18 patients. (2016) (1)
- P2.13-10 Ph I/II Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with Erlotinib in pts with EGFRm NSCLC (2018) (1)
- Stakeholder engagement to initiate lung cancer screening in an urban safety-net health system. (2020) (1)
- Intracranial hemorrhage during GliaSite RTS manipulation in an anticoagulated patient (2007) (1)
- Thyroid dysfunction and immune checkpoint inhibitor outcomes. (2020) (1)
- Upfront Brain Treatments Followed by Lung Surgery Improves Survival for Stage IV Non-small Cell Lung Cancer Patients With Brain Metastases: A Large Cohort Analysis (2021) (1)
- Intramedullary spinal cord hemorrhage after treatment with bevacizumab in a long-term survivor with metastatic non-small-cell lung cancer. (2014) (1)
- ALK mutation and inhibition in lung cancer (2017) (1)
- Variation in the assessment of immune-related adverse event occurrence, grade, and timing. (2019) (1)
- MA05.01 E6508: Phase II Study of Immunotherapy with Tecemotide and Bevacizumab after Chemoradiation in Unresectable Stage III NS-NSCLC (2018) (1)
- Stimulating an immune response through bavituximab in a phase III lung cancer study. (2014) (1)
- Decentralized Clinical Trials in Oncology: Are We Ready for a Virtual-First Paradigm? (2022) (1)
- P1.16-47 Adjuvant Targeted Therapy Following Standard Adjuvant Therapy for Resected NSCLC: An Initial Report from ALCHEMIST (Alliance A151216) (2018) (1)
- Does decompressive surgery improve outcome in patients with metastatic epidural spinal-cord compression? (2006) (1)
- An Emerging Lung Cancer Biomarker (2014) (1)
- Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology? (2021) (1)
- 21st Century Cures Act: Implementation Without Understanding Implication? (2021) (1)
- The association between clinical characteristics, treatment modality, and outcomes of non-small cell lung cancer. (2009) (1)
- Safety and Outcomes of Combining Immune Checkpoint Inhibitors with Radiation Therapy (2017) (1)
- The impact of renal function on therapeutic options for advanced non-small cell lung cancer (NSCLC). (2012) (1)
- The role of experience and clinical decision support in clinical trial accrual within oncology. (2021) (1)
- transplantation: implications for VTE prevention and bleeding among 1514 patients undergoing hematopoietic stem cell The incidence of and risk factors for venous thromboembolism (VTE) (2013) (1)
- Randomized phase II study of human anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody (IMC-3G3) with paclitaxel/carboplatin (P/C) or P/C alone in first-line treatment of stage IIIb/IV non-small cell lung cancer (NSCLC). (2010) (1)
- Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced NSCLC. (2022) (1)
- Targeted Therapy in Non-small Cell Lung Cancer (2011) (0)
- Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors (2022) (0)
- OA06.03 Serological Response to SARS-CoV-2 Vaccination in Patients Lung Cancer: A Mount Sinai-Led Prospective Matched Controlled Study (2022) (0)
- P1.16-01 Complications Associated with Lung Biopsies in Patients with Lung Cancer: A Population Based Analysis (2019) (0)
- Use of QTc-prolonging medications among patients with lung cancer: implications for clinical trials and standard clinical care. (2018) (0)
- Safety and tolerability of concurrent Nab-P (Nab-P) and Carbo (Carbo) with thoracic radiotherapy (RT) followed by consolidative Nab-P and Carbo in patients with stage IIIA/B non-small cell lung cancer (NSCLC). (2016) (0)
- AXL Inhibitors: Status of Clinical Development (2023) (0)
- Longitudinal Immune and Genomic Monitoring Reveals Signatures of Immune-related Adverse Events in Cancer Patients Receiving Checkpoint Inhibitor Therapy (2020) (0)
- Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA. (2022) (0)
- Prevalence and predictors of online patient access to electronic medical records among patients with cancer. (2013) (0)
- OA07.05 High-Grade Chemotherapy-Induced Peripheral Neuropathy (CIPN): An Analysis of ECOG-ACRIN Lung Cancer Clinical Trials (2019) (0)
- A New Role for Epigenetic Therapy (2014) (0)
- Abstract B32: RADIANCE: An open-label, nonrandomized, prospective biomarker study to assess analytic concordance between noninvasive testing and tissue testing for EGFR T790M mutation detection in patients with non-small cell lung cancer (2018) (0)
- Contemporary Lung Cancer Screening and the Promise of Blood-Based Biomarkers (2021) (0)
- Mobile device access to electronic patient portals in oncology: Potential implications for patient and practice experiences. (2018) (0)
- Abstract CT087: Concentration-dependent early anti-vascular and anti-tumor effects of itraconazole in non-small cell lung cancer (NSCLC) (2019) (0)
- Underlying host immune dysregulation in cancer patients developing immune-related adverse events. (2018) (0)
- Preventable patient acute mortality after EMR-generated QTc alerts. (2020) (0)
- Narrative review: molecular and genetic profiling of oligometastatic non-small cell lung cancer (2021) (0)
- Calculated versus measured creatinine clearance for the dosing of methotrexate in patients with primary CNS lymphoma. (2006) (0)
- P2.01-047 A Phase 1 Trial of Dose Escalated BGB324 in Combination with Docetaxel for Previously Treated Advanced NSCLC (2017) (0)
- Cancer Therapeutics Insights BIBF 1120 ( Nintedanib ) , a Triple Angiokinase Inhibitor , Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer (2013) (0)
- PS01.02: Thoracic Oncology Clinical Trial Eligibility Criteria: Ongoing Increase in Recent Years: Topic: Medical Oncology (2016) (0)
- Tracking the Non-Enrolled: Lung Cancer Screening Patterns Among Individuals Not Accrued to a Randomized Clinical Trial (2020) (0)
- A New Approach to Simplifying and Harmonizing Cancer Clinical Trials-Standardizing Eligibility Criteria. (2022) (0)
- MA 10.05 Improved Outcome for Immune Checkpoint Inhibitors (ICI) in Patients Previously Treated with Bavituximab in the SUNRISE Trial (2017) (0)
- Placing a Cancer Diagnosis in Clinical Context: Applying Functional Trajectories to Advanced NSCLC (2022) (0)
- Institutional scientific review of cancer clinical research protocols: Impact of requirement on activation timelines. (2017) (0)
- Prevalence of autoimmune conditions among patients with lung cancer: Implications for immunotherapy treatment options. (2016) (0)
- Development and use of a staffing model for clinical research teams at an NCI Comprehensive Cancer Center. (2016) (0)
- An Armored CAR for Leukemia Treatment (2014) (0)
- Use of chemotherapy for advanced non-small cell lung cancer in a contemporary and diverse patient population. (2010) (0)
- Correlating immune toxicity, blood cell counts, and overall survival in cancer patients receiving immune therapy. (2020) (0)
- "Pure and wholesome": Stephen Allen, cholera, and the nineteenth-century New York City water supply. (2013) (0)
- Immune dysregulation in cancer patients developing immune-related adverse events (2018) (0)
- Phase 0 Trial of Itraconazole for Early-Stage Non-Small Cell Lung Cancer (2015) (0)
- Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors (2023) (0)
- Phase II trial of clinical activity and safety of ceritinib combined with stereotactic ablative radiotherapy (SABR) in lung adenocarcinoma patients. (2020) (0)
- MA06.02 NSCLC Surgery Outcomes Between Facility Types and Association with Guideline Directed Surgical Quality of Care Metrics (2019) (0)
- Implementation of a Lung Cancer Screening Program in a Majority-Minority, Safety-Net Health System: Completion Rates and Radiological Findings in the First Two Years (2020) (0)
- P3.01-32 An Open-Label, Non-Randomized, Biomarker Study of Concordance in Non-Invasive and Tissue Tests for T790M Detection in NSCLC (2018) (0)
- Abstract PO-096: A guide for development of a successful and inclusive lung cancer research strategy based on U.S. best practices (2020) (0)
- Differences in lung cancer clinical trial accrual between a public and university medical oncology clinic. (2010) (0)
- Role of Nuclear Export Functions in Normal Cell Physiology and Cancer (2017) (0)
- 1st Line Pembrolizumab in Treatment of Stage IV NSCLC Patients – A Pattern of Failure Analysis with Associated Survival Outcomes (2022) (0)
- Pop - Suppl Data - Table 3 revised (2014) (0)
- P1.04-71 Tumor Burden Is Not Associated with Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer (2019) (0)
- Association between baseline tumor dimensions and survival in advanced non-small cell lung cancer (NSCLC). (2013) (0)
- YIA23-001: Targeting NKG2D Ligands Is Therapeutically Effective in NSCLC (2023) (0)
- Abstract 4484: ScRNA-seq of patients with immune-related adverse events and checkpoint inhibitor therapy (2020) (0)
- Survival among breast cancer patients with a history of previous cancer. (2020) (0)
- Presentation of early-stage non-small cell lung cancer (NSCLC) without radiographic screening: End of an era? (2011) (0)
- Better Late Than Never: Fully Incorporating Oncology Advanced Practice Providers Into Cancer Clinical Trials. (2022) (0)
- Radiation-induced KRAS G12V mutant lung adenocarcinoma in a never smoker (2016) (0)
- Do mRNA profiles of lung adenocarcinomas provide information that will help individual patients? (2020) (0)
- Circulating mitochondrial DNA as a biomarker for lung cancer screening (2021) (0)
- Preliminary correlative analysis of PD-L1 expression from the SUNRISE study. (2017) (0)
- Impact of Prior Cancer on Eligibility for Plasma Cell Disorder (PCD) Clinical Trials (2018) (0)
- Prevalence And Impact of Medical Comorbidities in A Real-World Lung Cancer Screening Population. (2022) (0)
- MYCing progress against immunosuppression-associated cancers (2015) (0)
- Docetaxel and bavituximab in nonsquamous NSCLC 1 Docetaxel Plus Bavituximab in Previously Treated , Advanced Nonsquamous Non – small-cell Lung Cancer (2016) (0)
- P1.16-41 Timing, Sites, and Correlates of Lung Cancer Recurrence: The Missing Pieces in National Datasets (2019) (0)
- 197TiP A phase 1/2 trial of selinexor combined with docetaxel for previously treated, advanced KRAS mutant non-small cell lung cancer (2018) (0)
- Survival among colorectal cancer patients with a history of previous cancer. (2020) (0)
- Treatment Guidance from the Blood (2014) (0)
- Antibody mediated blockade of phosphatidylserine to enhance immune checkpoint blockade by repolarizing immune suppressive mechanisms of the tumor microenvironment. (2016) (0)
- Cancer center clinic and clinical research team perceptions of identity and interactions. (2017) (0)
- Effect of prior cancer on outcomes in early stage lung cancer: Implications for clinical trial eligibility and accrual. (2016) (0)
- PP.48 Breakthrough SARS-CoV-2 Infection and COVID-19 Disease Severity in Lung Cancer Patients (2023) (0)
- Enhancing access to and diversity in cancer clinical trials through a financial reimbursement program: Protocol to evaluate a novel program. (2022) (0)
- Performance Status-Based Oncology Practice Guidelines: Easier Said Than Done. (2016) (0)
- Treatment and outcomes of primary pericardial mesothelioma: A systematic review. (2017) (0)
- Miscellaneous agents--cytotoxics and hormonal agents. (2012) (0)
- QIM22-197: Protected Time and Provision of Resources at National Comprehensive Cancer Network (NCCN) Member Institutions (MIs) (2022) (0)
- Drug exposure: still relevant after all these years (2021) (0)
- P1.07-031 Autoantibodies Associated with Risk of Subclinical Autoimmunity and Immune-Related Adverse Events from Checkpoint Inhibitor Therapy (2017) (0)
- Diagnosis and Management of a Patient with Limited Stage Small Cell Lung Cancer Detected by Low Dose Computed Tomography Screening (2020) (0)
- Expression of soluble DC-HIL/gpnmb receptor in the blood of metastatic non-small cell lung carcinoma treated with anti-PD1/PDL1 monoclonal antibodies. (2019) (0)
- Antibiotic Prescriptions in Lung Cancer and Melanoma Populations: Differences With Potential Clinical Implications in the Immunotherapy Era. (2022) (0)
- Supplementary Data CR Oct 13 (2014) (0)
- Expanding the role of advanced practice providers (APPs) in cancer clinical trials. (2022) (0)
- Consenting factors in clinical cancer research: Observations from a cancer center tissue repository. (2010) (0)
- P3.02c-051 A Pre-Treatment Serum Test Based on Complement and IL-10 Pathways Identifies Patients Benefiting from the Addition of Bavituximab to Docetaxel: Topic: IT (2017) (0)
- Finding Needles in the Haystack (2014) (0)
- Immune toxicity and flow cytometry of circulating blood cells in cancer patients receiving immune therapy. (2020) (0)
- Development and Validation of a Nomogram Prognostic Model for Small-Cell Lung Cancer Patients (2018) (0)
- Lung Cancer Computational Biology and Resources. (2021) (0)
- Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study (2022) (0)
- Impact of National Cancer Institute (NCI)-mandated scientific review on protocol development and content. (2014) (0)
- Distinct NSCLC EGFR Variants in a Family With Li-Fraumeni Syndrome: Case Report (2022) (0)
- Exploring the association between KRAS mutations and depression in non-small cell lung cancer (NSCLC) patients. (2017) (0)
- Impact of prior radiation on survival in metastatic lung cancer ECOG-ACRIN trials. (2017) (0)
- Abstract PS11-31: Survival among female breast cancer patients who have survived a previous cancer (2021) (0)
- MA02.10 The First Year of Implementing a Lung Cancer Screening Program in an Urban Safety-Net Health System (2018) (0)
- P2.01-37 A Ph 1/2 Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) with Docetaxel in pts with Previously Treated NSCLC (2018) (0)
- Exploring the Biology of HPV-Associated Head and Neck Cancer (2014) (0)
- Lessons learned from a lung cancer screening patient navigation program at a safety-net hospital system. (2022) (0)
- Acknowledgment of Reviewers 2021. (2021) (0)
- Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial (2021) (0)
- Cancer center staff effort related to electronic patient portal use: A growing demand. (2016) (0)
- P3.08-004 Phase I/II Trial of Nab-Paclitaxel or Paclitaxel Plus Carboplatin with Concurrent Radiation for Inoperable Stage IIIA/B NSCLC (2017) (0)
- Abstract 3368: Prevalence and significance of drug-drug interactions among patients with lung cancer (2019) (0)
- Attitudes toward clinical research: an analysis of 922 patients in a university-based tissue repository (2008) (0)
- PS01.21: Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials: Topic: Pathology (2016) (0)
- Abstract IA3: Lung cancer stem cells, acquired vulnerabilities, and molecular portraits: Translation to the clinic (2012) (0)
- Can Milk Do Harm? (2014) (0)
- Prevalence and prognostic impact of prior cancer in locally advanced lung cancer. (2015) (0)
- 98P Trends in and impact of hospital-acquired adverse events in patients with lung cancer undergoing lung resection (2018) (0)
- Cancer Clinical Trials Beyond Pandemic: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion (2022) (0)
- Thirteen-Year Survival in a Patient With Diffuse Bilateral Lepidic-Predominant Adenocarcinoma: A Case Report of Lung Transplantation and Local Salvage (2020) (0)
- The effects of targeting stromal and tumor cell platelet-derived growth factor receptor (PDGFR) in non-small cell lung cancer (NSCLC). (2011) (0)
- Simultaneous acute myeloid leukemia and mesothelioma diagnoses in a long-term survivor of the 1984 Bhopal gas leak (2014) (0)
- Pop - Suppl Data - Table 1 (2014) (0)
- 30PProteomic signature analysis and application in clinical development of the novel phosphatidylserine-targeting immunotherapy, bavituximab (2016) (0)
- Stromal and antitumor effects of BIBF 1120 (nintedanib) in a preclinical lung cancer model. (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With David E. Gerber?
David E. Gerber is affiliated with the following schools:
